If you're looking into weight loss support through the HSE in Ireland for 2026, there's a mix of free services, medication options, and eligibility rules to know about. With obesity affecting around one in four Irish adults, the demand for effective treatments is rising. The HSE continues to expand its offerings, balancing medical treatments with lifestyle interventions.
Key Figures and Quick Facts
- About 25% of the Irish population is affected by obesity, equating to roughly 1.2 million people as of the latest 2023 health data.
- The HSE currently funds Saxenda (liraglutide) for obesity treatment, available under medical card schemes since 2022.
- Wegovy (semaglutide), another GLP-1 receptor agonist, has been authorised for obesity treatment in the EU since 2023 and is under assessment for medical card coverage in Ireland; the evaluation period will probably last about 18 weeks, with a decision anticipated by mid-2026.
- Weight loss injections like Saxenda and potentially Wegovy are likely limited to adults with a body mass index (BMI) over 35 plus obesity-related complications such as diabetes, hypertension, or sleep apnea — this group represents approximately 80,000 eligible people nationally.
- Ozempic (semaglutide) is currently funded only for Type 2 Diabetes patients and isn't approved or funded for obesity treatment under HSE schemes.
- Illegal and counterfeit weight loss drugs have been on the rise, posing a public health risk; the HSE has issued warnings about unregulated online purchases.
- The HSE Drug Payment Scheme allows patients without medical cards to cap monthly medication costs at €114, potentially covering approved weight loss drugs pending reimbursement decisions in 2026.
- The HSE's national clinical lead for obesity, Professor Donal O’Shea, has indicated ongoing policy alignment with UK standards, which include expanded access to medications and multidisciplinary weight management.
- Reimbursement assessments for new weight loss medications weigh their health benefits against financial costs, with typical evaluation periods around 18 weeks before pricing and coverage decisions.
- Free support services include lifestyle advice, dietetic services, psychological support, and community weight management programmes delivered through primary care and specialised clinics.
- National obesity management guidelines recommend a stepped approach, starting with lifestyle interventions and progressing to medication or surgery for eligible patients.
Overview of HSE Weight Loss Services in 2026
The HSE offers a range of weight loss services aimed at individuals struggling with obesity or overweight conditions, particularly those with associated complications. Free support includes access to registered dietitians, lifestyle counselling, and structured weight management programmes available at community health centres and through primary care teams.
These programmes often involve multidisciplinary teams including nurses, dietitians, physiotherapists, and sometimes psychologists. They focus on dietary changes, increased physical activity, and behavioural therapies to support sustainable weight loss. For instance, the HSE’s Community Weight Management Programme has seen participation rates rise by 15% from 2022 to 2024, reflecting growing awareness and demand.
On the medication front, Saxenda remains the only obesity drug fully funded by the HSE for medical card holders. Saxenda is administered as a daily injection and costs approximately €1,200 per month without subsidy. The HSE covers this cost for eligible patients, easing access significantly.
Wegovy, which contains semaglutide, has demonstrated in clinical trials an average weight loss of 15% body weight over 68 weeks. It's administered once weekly and, if approved for funding after the ongoing 18-week assessment period, could become available to medical card holders by late 2026. The estimated cost of Wegovy in Ireland is around €900 per month, potentially lower under HSE agreements.
Weight loss injections are targeted primarily at adults with a BMI over 35, especially those with obesity-related health issues like Type 2 Diabetes, cardiovascular disease, or obstructive sleep apnea. This eligibility criterion narrows the pool to about 80,000 people nationally, based on health statistics from 2023.
Ozempic remains off-label for weight loss and is only funded for diabetes management, despite some patients seeking it for weight loss. The HSE warns against using medications outside approved indications due to safety and reimbursement policies.
The rise in demand for weight loss medications has also highlighted the risks of unregulated products. The HSE has identified and issued warnings about counterfeit drugs sold online, which may contain harmful substances. Public education campaigns in 2025 have aimed to reduce the use of illegal drugs and encourage patients to seek medical advice.
Regional Differences in Access and Services
Access to weight loss services varies across Ireland's regions. Urban areas like Dublin, Cork, and Galway have more specialised obesity clinics and easier access to dietetic and psychological services. For example, Dublin hosts three multidisciplinary obesity clinics funded by the HSE, while some rural counties have fewer than one such clinic per 100,000 population.
Community weight management programmes are more widely available in the eastern region, with participation rates 20% higher than in western and midland regions. This disparity is partly due to resource allocation and workforce availability.
Medical card coverage is consistent nationwide, but the number of patients receiving Saxenda varies. Dublin reports around 3,500 active Saxenda prescriptions, while counties like Mayo and Donegal report fewer than 200 each. This reflects differences in healthcare infrastructure and referral patterns.
Telehealth consultations for weight management have expanded, especially post-pandemic, helping rural patients access dietitian services. In 2025, telehealth appointments for weight loss support increased by 35% compared to 2023.
However, some rural areas report longer wait times for specialist clinics — averaging 16 weeks versus 8 weeks in urban centres. The HSE has announced plans to increase staffing and expand access in underserved areas by 2027.
Forecast for Weight Loss Services and Medication in 2026 and Beyond
The outlook for HSE weight loss services in 2026 is one of gradual expansion and increased medication access. With Wegovy’s reimbursement assessment underway, approval could broaden treatment options for thousands of patients currently unable to access effective medications.
Health economists estimate that if Wegovy is funded, up to 50,000 additional patients could receive weight loss medication annually, potentially reducing obesity-related hospital admissions by 10% over five years.
The HSE is also expected to enhance community programmes, investing an estimated €5 million in 2026 to increase dietetic staffing and expand psychological support services for behaviour change.
Meanwhile, ongoing public health campaigns will continue to tackle illegal drug use and promote safe, evidence-based weight loss methods.
National guidelines are being revised to reflect emerging evidence, encouraging earlier intervention with medications alongside lifestyle changes. The approach aims to improve long-term outcomes and reduce obesity prevalence, which has grown by nearly 3% between 2020 and 2023.
Looking further ahead, the HSE is exploring pilot programmes for combination therapies and digital weight management tools, aiming to support personalised care. These pilots could start in late 2026 or 2027, pending funding and evaluation.
The HSE’s weight loss services in Ireland for 2026 offer a mix of free support and emerging medication options. Saxenda remains the main funded drug, while Wegovy awaits final approval that could broaden access significantly. With roughly 1.2 million adults affected by obesity, these services will be critical in addressing the growing public health challenge. Regional disparities in access persist, but telehealth and increased investment aim to close gaps. The next few years will see expanded options and integrated care models shaping obesity treatment across Ireland.
This article was created with AI assistance.
